Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer
October 12 2021 - 8:00AM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development
of medicines that control the expression of genes, today announced
the appointment of Jason Haas as Chief Financial Officer. Mr. Haas
brings more than 25 years of healthcare investment banking and
corporate finance experience to Syros.
“We are pleased to welcome Jason to Syros, who brings an
exceptional depth of financial, strategic, and leadership
experience in the life sciences space,” said Nancy Simonian, M.D.,
Chief Executive Officer of Syros. “Jason has a proven track record
as a strategic advisor to biotechnology and pharmaceutical
companies across all stages of development. He joins Syros at a
pivotal time, as we advance towards becoming a commercial-stage
company, with a growing portfolio in targeted hematology and
selective CDK inhibition.”
Mr. Haas most recently served as Co-Head of Americas, Healthcare
Investment Banking at Barclays, where he executed an array of
strategic transactions across the public and private markets, and
supported companies through equity and debt financings, mergers and
acquisitions, divestitures, and spin-offs. Prior to joining
Barclays in 2016, he served as Head of Americas, Healthcare
Investment Banking at Deutsche Bank. Prior to his role at Deutsche
Bank, he was a Managing Director on the Healthcare Investment
Banking team at Goldman Sachs & Co, where he covered life
sciences companies. Mr. Haas holds an M.B.A in Finance from
Columbia Business School and a B.A in International Relations and
Economics from Colgate University.
“I am excited to join Syros at such an exciting time in the
company’s trajectory, with multiple programs progressing through
clinical development, each with the potential to set a new standard
of care for patients,” said Mr. Haas. “I look forward to working
with the team in support of building a fully integrated
biopharmaceutical company that brings medicines to the market for
patients, where there is a significant unmet need, and to drive
long-term value for shareholders.”
About Syros Pharmaceuticals Syros is redefining the power
of small molecules to control the expression of genes. Based on its
unique ability to elucidate regulatory regions of the genome, Syros
aims to develop medicines that provide a profound benefit for
patients with diseases that have eluded other genomics-based
approaches. Syros is advancing a robust clinical-stage pipeline,
including: tamibarotene, a first-in-class oral selective RARα
agonist in RARA-positive patients with higher-risk myelodysplastic
syndrome and acute myeloid leukemia; SY-2101, a novel oral form of
arsenic trioxide in patients with acute promyelocytic leukemia; and
SY-5609, a highly selective and potent oral CDK7 inhibitor in
patients with select solid tumors and blood cancers. Syros also has
multiple preclinical and discovery programs in oncology and
monogenic diseases.
Cautionary Note Regarding Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995,
including without limitation statements regarding Syros’s ability
to advance towards becoming a commercial-stage company and the
potential of Syros’s programs to set new standards of care. The
words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’
‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’
‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’
‘‘would,’’ and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in these forward-looking statements as a
result of various important factors, including Syros’ ability to:
advance the development of its programs under the timelines it
projects in current and future clinical trials; demonstrate in any
current and future clinical trials the requisite safety, efficacy
and combinability of its drug candidates; replicate scientific and
non-clinical data in clinical trials; successfully develop a
companion diagnostic test to identify patients with the RARA
biomarker; obtain and maintain patent protection for its drug
candidates and the freedom to operate under third party
intellectual property; obtain and maintain necessary regulatory
approvals; identify, enter into and maintain collaboration
agreements with third parties, including its ability to perform
under its collaboration agreements with Incyte Corporation and
Global Blood Therapeutics; manage competition; manage expenses;
raise the substantial additional capital needed to achieve its
business objectives; attract and retain qualified personnel; and
successfully execute on its business strategies; risks described
under the caption “Risk Factors” in Syros’ Annual Report on Form
10-K for the year ended December 31, 2020 and Quarterly Report on
Form 10-Q for the quarter ended June 30, 2021, each of which is on
file with the Securities and Exchange Commission; and risks
described in other filings that Syros makes with the Securities and
Exchange Commission in the future. In addition, the extent to which
the COVID-19 outbreak continues to impact our workforce and our
discovery research, supply chain and clinical trial operations
activities, and the operations of the third parties on which we
rely, will depend on future developments, which are highly
uncertain and cannot be predicted with confidence, including the
duration and severity of the outbreak, additional or modified
government actions, and the actions that may be required to contain
the virus or treat its impact. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Syros expressly disclaims any obligation to update any
forward-looking statements, whether because of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211012005031/en/
Media Courtney Solberg Syros Pharmaceuticals 917-698-9253
csolberg@syros.com
Investors Hannah Deresiewicz Stern Investor Relations,
Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2023 to Apr 2024